大麻和儿科大麻暴露 - 来自美国中毒中心的证据
Shelby R Steuart1, Victoria Bethel2, W David Bradford2
1University of Chicago, Chicago, IL, USA.
Journal of child psychology and psychiatry, and allied disciplines
|October 12, 2025
概括
医用大麻药房与儿童大麻暴露的增加有关,特别是在幼儿中. 然而,休药店的开口显示暴露率下降,这表明潜在的缓解效应.
科学领域:
- 公共卫生 公共卫生
- 毒理学 毒理学 毒理学
- 大麻研究 大麻研究
背景情况:
- 有限的全国数据存在于大麻合法化对儿科暴露的影响.
- 国家毒素数据系统 (NPDS) 用于评估儿童与大麻相关的暴露.
- 这项研究调查了医疗和娱乐大麻药房对儿科暴露的影响.
研究的目的:
- 评估大麻药房开业与儿童大麻暴露之间的关联.
- 为了区分医疗与娱乐大麻药房对暴露率的影响.
- 分析不同儿科年龄组的暴露趋势.
主要方法:
- 从2016年至2021年,对36161名2至20岁的个人进行了与大麻有关的暴露的分析.
- 拥有和没有医用大麻药房的州和拥有娱乐用药房的州的比较.
- 使用差异差异设计来估计药房开业对半年风险的影响.
主要成果:
- 医用大麻药房开业与2-6岁儿童暴露率增加52.3%有关.
- 与只有医疗诊所的州相比,休诊所的开业显示暴露率下降了42.4%.
- 在7至11岁的儿童中,在休药房开业后,观察到暴露的显著下降.
结论:
- 决策者应在开设医疗药房时考虑大麻安全教育倡议.
- 开设休诊所可能会部分缓解与医疗诊所相关的暴露风险增加.
- 医用大麻州的医疗保健提供者应该教育患者安全的大麻储存和使用,以防止儿童暴露.
相关概念视频
Prevention of Further Absorption of Poison
1.2K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
671
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
671
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
242
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
Pharmacokinetics in Pediatric Patients: Drug Metabolism
192
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
192
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212


